藤济

Shanghai Tengji Pharmaceutical Technology is a clinical-stage biotechnology company specializing in the discovery and development of innovative peptide-based therapies for metabolic diseases. The company's primary focus is on multi-target agonists that simultaneously activate the GLP-1, GIP, and glucagon receptors to achieve synergistic effects in weight reduction and glucose regulation. Its lead asset, TJ-103, is currently in Phase 2 clinical trials for obesity and type 2 diabetes, positioning the company as a competitive player in the metabolic drug space. Tengji utilizes a proprietary technology platform to engineer long-acting peptides with optimized safety and efficacy profiles. Headquartered in Shanghai, the company is backed by prominent venture capital firms and led by a team with extensive experience in metabolic drug R&D.